Immunovant, Inc. IMVT Business Segments — Share-Based Payment Arrangement, Expense
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Immunovant, Inc. in its filing.
Tagged under the XBRL concept us-gaap:AllocatedShareBasedCompensationExpense.
The official record: Immunovant, Inc.’s 10-K, filed May 20, 2026, on SEC EDGAR. View the filing →
Ask your AI about Immunovant, Inc.'s business segments — share-based payment arrangement, expense.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Immunovant, Inc.'s business segments — share-based payment arrangement, expense?
- Immunovant, Inc. (IMVT) reported business segments — share-based payment arrangement, expense of $6.28M in Q1 2026.
- How has Immunovant, Inc.'s business segments — share-based payment arrangement, expense changed year-over-year?
- Immunovant, Inc.'s business segments — share-based payment arrangement, expense decreased by 2.9% year-over-year, from $6.47M to $6.28M.
- What is the long-term trend for Immunovant, Inc.'s business segments — share-based payment arrangement, expense?
- Over 3 years (2023 to 2026), Immunovant, Inc.'s business segments — share-based payment arrangement, expense has grown at a 22.9% compound annual growth rate (CAGR), from $17.49M to $32.49M.
- What does business segments — share-based payment arrangement, expense mean?
- Represents the non-cash compensation expense recognized for equity-based awards granted to employees and directors within the segment. This metric reflects the cost of aligning the interests of the workforce with shareholders through stock options or restricted stock units. It is essential for understanding the true economic cost of human capital and potential shareholder dilution.